))
NewLimit Raises $130M to Reverse Cellular Aging
Archived series ("Inactive feed" status)
When?
This feed was archived on October 02, 2025 22:13 (
Why? Inactive feed status. Our servers were unable to retrieve a valid podcast feed for a sustained period.
What now? You might be able to find a more up-to-date version using the search function. This series will no longer be checked for updates. If you believe this to be in error, please check if the publisher's feed link below is valid and contact support to request the feed be restored or if you have any other concerns about this.
Manage episode 481212741 series 3660759
Jacob Kimmel, co-founder and President of NewLimit, joins us to talk about the company’s newly announced $130 million Series B and its ambitious plan to develop reprogramming-based medicines that can reverse cellular aging.
We explore how NewLimit’s therapies use mRNA to deliver transcription factors that restore liver cells to a younger state, why the company is targeting alcohol-related liver disease first, and how advances in single-cell sequencing and AI made this work possible. Jacob also shares how NewLimit is expanding into the immune and endothelial systems—and what that could mean for extending human healthspan.
We also covered OpenAI’s acquisition of Windsurf, DoorDash’s Deliveroo and SevenRooms deals, Legora’s new raise in legal AI, and Uber’s $700M push into Turkey’s delivery market.
47 episodes
Share
